Eli Lilly has reduced the price of its weight-loss drug, Zepbound, to combat competition from compounding pharmacies and Novo ...

Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...

We recently published a list of Jim Cramer Discusses These 12 Stocks & Trump DOJ’s Action Against Health Insurance Companies.

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

Compounding pharmacy and IBD 50 newcomer Hims & Hers Health reported bullish earnings and sales growth late Monday. But Hims ...

Investing.com - Eli Lilly (NYSE:LLY) announced on Tuesday that it would begin selling 7.5 milligram and 10 milligram single-dose vials of its Zepbound weight-loss drug at a roughly $150 discount to ...

Eli Lilly has cut the price for vials of its weight-loss drug Zepbound sold online and expanded the range of doses in an ...

MarketWatch was able to verify Zeng's claims via videos and was also able to order delivery of Ozempic to an address in China. The price was 798 yuan ($108) for a one-month supply that is injected ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

The American pharmaceutical company has started selling higher doses of Zepbound, as it seeks to spur demand for the medicine ...

Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.

Eli Lilly has reduced the price of its weight-loss drug Zepbound, offering higher doses in vials at a discount to boost demand and compete with Novo Nordisk's Wegovy. The price adjustment aims to ease ...